Compare
Biovie Inc. vs Exicure, Inc. vs Actuate Therapeutics, Inc. vs CytoDyn Inc.
| Latest fiscal year | Biovie Inc. BIVI | Exicure, Inc. XCUR | Actuate Therapeutics, Inc. ACTU | CytoDyn Inc. CYDY |
|---|---|---|---|---|
| Year ended | 2026-06-30 | 2025-12-31 | 2025-12-31 | 2026-05-31 |
| Revenue | n/a | $0 | n/a | n/a |
| Revenue growth (YoY) | n/a | -100.0% | n/a | n/a |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/a | n/a | n/a |
| Net margin | n/a | n/a | n/a | n/a |
| Net income | -$22.07M | -$4.95M | -$22.23M | -$42.70M |
| EPS (Diluted) | -$3.05 | -$0.79 | -$1.06 | -$0.03 |
| Operating cash flow | -$19.02M | -$8.55M | -$19.21M | -$17.25M |
| Free cash flow | n/a | -$8.56M | n/a | n/a |
| Cash & equivalents | $8.98M | n/a | $13.16M | $11.85M |
| Total assets | $14.25M | $14.04M | $14.04M | $13.97M |
| Total liabilities | $3.98M | $10.12M | $6.11M | $123.69M |
| Shareholders' equity | $10.27M | $3.93M | $7.92M | -$109.72M |
| Return on year-end equity | -214.9% | -126.0% | -280.5% | n/a |
| Shares outstanding | 7.54M | 6.37M | 23.25M | 1.37B |
Revenue, most recent five fiscal years
| Fiscal year | Biovie Inc. | Exicure, Inc. | Actuate Therapeutics, Inc. | CytoDyn Inc. |
|---|---|---|---|---|
| Latest | n/a | $0 Ended 2025-12-31 | n/a | $0 Ended 2023-05-31 |
| 1 year earlier | n/a | $500.0K Ended 2024-12-31 | n/a | $266.0K Ended 2022-05-31 |
| 2 years earlier | n/a | $0 Ended 2023-12-31 | n/a | $0 Ended 2021-05-31 |
| 3 years earlier | n/a | $28.83M Ended 2022-12-31 | n/a | n/a |
| 4 years earlier | n/a | -$483.0K Ended 2021-12-31 | n/a | n/a |